EGFR and colorectal carcinoma: Off note, this is also the reason why PIK3CA mutations in the helical domain are discussed as a cause of resistance to, for example, EGFR inhibitor therapy and are being investigated in clinical trials (C-PRECISE-01, NCT04495621) as a target in such CRC entities [102].